The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.

At endpoint (week 24, last observation carried forward), memantine-treated patients significantly outperformed placebo-treated patients on the SIB (least squares mean difference [95 % CI] 2.6 [1.0, 4.2]; p = 0.001), CIBIC-Plus ( p = 0.008), NPI ( p = 0.005), and verbal fluency test ( p = 0.004); the effect did not achieve significance on ADCS–ADL 19 ( p = 0.177).

also in 1,397 other papers